Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Loading...
Community
/
United States
/
Pharmaceuticals & Biotech
/
Madrigal Pharmaceuticals
Create a narrative
Madrigal Pharmaceuticals Community
NasdaqGS:MDGL Community
3
Narratives
written by author
0
Comments
on narratives written by author
18
Fair Values set
on narratives written by author
Community Investing Ideas
Madrigal Pharmaceuticals
Popular
Undervalued
Overvalued
Madrigal Pharmaceuticals
AN
AnalystConsensusTarget
Based on Analyst Price Targets
US Patent And EU Expansion Will Secure Future Potential
Key Takeaways Decades of patent protection and growing disease prevalence position Rezdiffra for sustained revenue growth, market expansion, and pricing power. International launches, pipeline diversification, and solid financial resources reduce risk and support expansion into new markets and indications.
View narrative
US$481.85
FV
8.0% undervalued
intrinsic discount
67.24%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
7
users have followed this narrative
Updated
narrative
Madrigal Pharmaceuticals
AN
AnalystHighTarget
Community Contributor
Rising Obesity And Aging Trends Will Drive NASH Therapy Adoption
Key Takeaways Rapid adoption of Rezdiffra, patent exclusivity, and first-mover momentum position Madrigal for accelerated revenue growth and margin expansion beyond consensus expectations. Strategic business development, strong financial resources, and advances in diagnostics and care models support broad market expansion, recurring revenue, and superior long-term earnings power.
View narrative
US$567
FV
21.9% undervalued
intrinsic discount
91.70%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
19 days ago
author updated this narrative
Madrigal Pharmaceuticals
AN
AnalystLowTarget
Community Contributor
US Pricing Pressure And European Payers Will Erode Margins
Key Takeaways Heavy dependence on a single asset and aggressive market competition threaten both revenue growth and long-term market share. Expansion into Europe and persistent high expenses are likely to strain margins and hinder profitability due to pricing pressures and limited pipeline diversity.
View narrative
US$311.98
FV
42.0% overvalued
intrinsic discount
56.73%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
26 days ago
author updated this narrative